Go Pro
→ The cat is out the bag (From Porter & Company) (Ad)tc pixel Free GNCA Stock Alerts

Genocea Biosciences (GNCA) Competitors

Genocea Biosciences logo
Compare

GNCA vs. SCPS, SMFL, NAVB, ADTX, and ARDS

Should you buy Genocea Biosciences stock or one of its competitors? Genocea Biosciences's main competitors and comparable companies include Scopus BioPharma (SCPS), Smart for Life (SMFL), Navidea Biopharmaceuticals (NAVB), Aditxt (ADTX), and Aridis Pharmaceuticals (ARDS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Genocea Biosciences compare to Scopus BioPharma?

Genocea Biosciences (NASDAQ:GNCA) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Scopus BioPharma has lower revenue, but higher earnings than Genocea Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

Scopus BioPharma's return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
Scopus BioPharma N/A N/A N/A

Genocea Biosciences has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.19, meaning that its share price is 119% less volatile than the broader market.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Scopus BioPharma Neutral

0.6% of Genocea Biosciences shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Scopus BioPharma beats Genocea Biosciences on 4 of the 7 factors compared between the two stocks.

How does Genocea Biosciences compare to Smart for Life?

Genocea Biosciences (NASDAQ:GNCA) and Smart for Life (NASDAQ:SMFL) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

Genocea Biosciences has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market. Comparatively, Smart for Life has a beta of 15.1, meaning that its share price is 1,410% more volatile than the broader market.

Smart for Life's return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
Smart for Life N/A N/A N/A

Smart for Life has higher revenue and earnings than Genocea Biosciences. Smart for Life is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

0.6% of Genocea Biosciences shares are held by institutional investors. Comparatively, 28.4% of Smart for Life shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by insiders. Comparatively, 31.7% of Smart for Life shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Smart for Life Neutral

Summary

Smart for Life beats Genocea Biosciences on 8 of the 9 factors compared between the two stocks.

How does Genocea Biosciences compare to Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market.

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Genocea Biosciences Neutral

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Navidea Biopharmaceuticals' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Genocea Biosciences N/A -182.88%-62.76%

Navidea Biopharmaceuticals has higher earnings, but lower revenue than Genocea Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A

Summary

Navidea Biopharmaceuticals beats Genocea Biosciences on 6 of the 9 factors compared between the two stocks.

How does Genocea Biosciences compare to Aditxt?

Aditxt (NASDAQ:ADTX) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, Aditxt's average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Aditxt Neutral
Genocea Biosciences Neutral

Aditxt has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market.

Genocea Biosciences has higher revenue and earnings than Aditxt. Aditxt is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aditxt$14.34K0.39-$41.71M-$100.79 thousandN/A
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A

Genocea Biosciences has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Genocea Biosciences' return on equity of -182.88% beat Aditxt's return on equity.

Company Net Margins Return on Equity Return on Assets
Aditxt-360,152.50% -374.60% -105.93%
Genocea Biosciences N/A -182.88%-62.76%

Given Genocea Biosciences' higher probable upside, analysts clearly believe Genocea Biosciences is more favorable than Aditxt.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aditxt
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Genocea Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

15.5% of Aditxt shares are owned by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are owned by institutional investors. 0.0% of Aditxt shares are owned by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Genocea Biosciences beats Aditxt on 9 of the 12 factors compared between the two stocks.

How does Genocea Biosciences compare to Aridis Pharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are held by institutional investors. 5.5% of Aridis Pharmaceuticals shares are held by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Aridis Pharmaceuticals has higher earnings, but lower revenue than Genocea Biosciences. Genocea Biosciences is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aridis PharmaceuticalsN/AN/A-$30.37M$0.310.00
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A

In the previous week, Aridis Pharmaceuticals had 1 more articles in the media than Genocea Biosciences. MarketBeat recorded 1 mentions for Aridis Pharmaceuticals and 0 mentions for Genocea Biosciences. Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Aridis Pharmaceuticals Neutral
Genocea Biosciences Neutral

Aridis Pharmaceuticals has a beta of 49.66, suggesting that its stock price is 4,866% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market.

Aridis Pharmaceuticals' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Aridis PharmaceuticalsN/A N/A N/A
Genocea Biosciences N/A -182.88%-62.76%

Summary

Aridis Pharmaceuticals beats Genocea Biosciences on 9 of the 10 factors compared between the two stocks.

Get Genocea Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for GNCA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GNCA vs. The Competition

Export
MetricGenocea BiosciencesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$6K$12.25B$7.26B$12.73B
Dividend YieldN/A2.59%2.53%8.86%
P/E Ratio0.00787.27273.2925.25
Price / SalesN/A754.88623.6797.64
Price / CashN/A94.8077.8252.26
Price / BookN/A12.3312.926.14
Net Income-$33.20M$2.82B$3.47B$349.01M

Genocea Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91MN/A70
SCPS
Scopus BioPharma
N/A$0.00
flat		N/AN/A$17KN/AN/A9
SMFL
Smart for Life
N/A$0.00
flat		N/A-92.6%$14K$11.11MN/A110
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10
ADTX
Aditxt
0.174 of 5 stars		$0.01
+5.5%		N/A-100.0%$5K$14.34KN/A60

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:GNCA) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners
The 2026 beginners Guide to Gold IRAs
Gold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...
Goldco Direct, LLC | Sponsoredtc pixel
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Are you leaving Social Security money on the table?
Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....
Money Pickle | Sponsoredtc pixel
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel